bioMerieux (OTCMKTS:BMXMF – Get Free Report) is anticipated to release its resultson Tuesday, July 28th. Analysts expect the company to post earnings of $2.44 per share and revenue of $2.2103 billion for the quarter.
bioMerieux Stock Down 0.4%
OTCMKTS BMXMF opened at $80.31 on Tuesday. bioMerieux has a 12 month low of $77.00 and a 12 month high of $152.00. The company’s 50-day moving average price is $81.75 and its 200-day moving average price is $100.94. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.48 and a current ratio of 2.39.
Analyst Ratings Changes
Several equities research analysts have issued reports on BMXMF shares. Zacks Research raised shares of bioMerieux to a “hold” rating in a research report on Tuesday, April 28th. UBS Group lowered shares of bioMerieux from a “buy” rating to a “neutral” rating in a research report on Monday, June 1st. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of bioMerieux in a research note on Wednesday, June 17th. Piper Sandler assumed coverage on bioMerieux in a research note on Thursday, June 11th. They issued a “neutral” rating on the stock. Finally, Morgan Stanley downgraded bioMerieux from an “overweight” rating to an “underweight” rating in a report on Tuesday, June 23rd. Five investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce”.
About bioMerieux
bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.
Featured Stories
- Five stocks we like better than bioMerieux
- The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
- Is Domino’s Stock Serving Up a Buying Opportunity?
- A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free
- Why Gold Miners Could Be the Market’s Biggest Comeback Story
Receive News & Ratings for bioMerieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioMerieux and related companies with MarketBeat.com's FREE daily email newsletter.
